ZA200206172B - Fusion protein having enhanced in vivo activity of erythropoietin. - Google Patents

Fusion protein having enhanced in vivo activity of erythropoietin.

Info

Publication number
ZA200206172B
ZA200206172B ZA200206172A ZA200206172A ZA200206172B ZA 200206172 B ZA200206172 B ZA 200206172B ZA 200206172 A ZA200206172 A ZA 200206172A ZA 200206172 A ZA200206172 A ZA 200206172A ZA 200206172 B ZA200206172 B ZA 200206172B
Authority
ZA
South Africa
Prior art keywords
erythropoietin
enhanced
fusion protein
vivo activity
vivo
Prior art date
Application number
ZA200206172A
Other languages
English (en)
Inventor
Bo-Sup Chung
Ki-Wan Kim
Dong-Eok Lee
Myung-Suk Oh
Ji-Sook Park
Original Assignee
Cheil Jedang Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cheil Jedang Corp filed Critical Cheil Jedang Corp
Publication of ZA200206172B publication Critical patent/ZA200206172B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/524Thrombopoietin, i.e. C-MPL ligand
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/505Erythropoietin [EPO]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA200206172A 2001-11-29 2002-08-02 Fusion protein having enhanced in vivo activity of erythropoietin. ZA200206172B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR10-2001-0074975A KR100467750B1 (ko) 2001-11-29 2001-11-29 생체내 에리스로포이에틴 활성이 증진된 융합단백질

Publications (1)

Publication Number Publication Date
ZA200206172B true ZA200206172B (en) 2003-04-03

Family

ID=36821313

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200206172A ZA200206172B (en) 2001-11-29 2002-08-02 Fusion protein having enhanced in vivo activity of erythropoietin.

Country Status (23)

Country Link
US (1) US7098318B2 (xx)
EP (1) EP1319712B1 (xx)
JP (1) JP3860097B2 (xx)
KR (1) KR100467750B1 (xx)
CN (1) CN100390201C (xx)
AR (1) AR036384A1 (xx)
AT (1) ATE460483T1 (xx)
AU (1) AU2002300359B2 (xx)
BR (1) BRPI0203394B1 (xx)
CA (1) CA2394572C (xx)
DE (2) DE60235603D1 (xx)
ES (1) ES2339426T3 (xx)
FR (1) FR2832716B1 (xx)
GB (1) GB2382580B (xx)
IT (1) ITMI20021803A1 (xx)
MX (1) MXPA02008131A (xx)
MY (1) MY122935A (xx)
NZ (1) NZ520442A (xx)
RU (1) RU2225220C1 (xx)
SG (1) SG117416A1 (xx)
TW (1) TWI237056B (xx)
WO (1) WO2003046013A1 (xx)
ZA (1) ZA200206172B (xx)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7345019B1 (en) * 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
CA2539440A1 (en) * 2003-09-29 2005-04-14 Warren Pharmaceuticals, Inc. Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
US7625564B2 (en) 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US7553941B2 (en) * 2006-02-03 2009-06-30 Modigene Inc Long-acting polypeptides and methods of producing same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US8067548B2 (en) 2007-07-26 2011-11-29 Novagen Holding Corporation Fusion proteins having mutated immunoglobulin hinge region
CN101863982A (zh) * 2009-04-17 2010-10-20 哈药集团生物工程有限公司 一种用于升高血小板的融合蛋白及其制备方法
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
CN103864913A (zh) * 2012-12-18 2014-06-18 联亚生技开发股份有限公司 重组蛋白
WO2014159813A1 (en) 2013-03-13 2014-10-02 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
AU2016280867B2 (en) 2015-06-19 2020-02-27 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
CA3030533A1 (en) 2016-07-11 2018-01-18 Oren HERSHKOVITZ Long-acting coagulation factor vii and methods of producing same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU648020B2 (en) * 1989-02-21 1994-04-14 Washington University Modified forms of reproductive hormones
AU5355790A (en) * 1989-04-19 1990-11-16 Cetus Corporation Multifunctional m-csf proteins and genes encoding therefor
US5856298A (en) * 1989-10-13 1999-01-05 Amgen Inc. Erythropoietin isoforms
ZA946122B (en) * 1993-08-17 1995-03-20 Amgen Inc Erythropoietin analogs
GB2285446B (en) * 1994-01-03 1999-07-28 Genentech Inc Thrombopoietin
ITFI940106A1 (it) * 1994-05-27 1995-11-27 Menarini Ricerche Sud Spa Molecola ibrida di formula gm-csf-l-epo o epo-l-gm-csf per la stimolaz ione eritropoietica
AU4658596A (en) * 1995-02-03 1996-08-21 G.D. Searle & Co. Novel c-mpl ligands
US6242570B1 (en) * 1997-07-10 2001-06-05 Beth Israel Deaconess Medical Center Production and use of recombinant protein multimers with increased biological activity
AU8182298A (en) * 1997-07-10 1999-02-08 Beth Israel Deaconess Medical Center Recombinant erythropoietin / immunoglobulin fusion proteins
EP1881005B1 (en) * 1997-07-14 2013-04-03 Bolder Biotechnology, Inc. Derivatives of G-CSF and related proteins
US6342220B1 (en) * 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
WO1999057147A1 (fr) * 1998-04-30 1999-11-11 Kirin Brewery Company, Limited Mutants de la thrombopoietine humaine
EP1200124B1 (en) * 1999-07-13 2008-09-10 Bolder Biotechnology, Inc. Erythropoietin-immunoglobulin fusion proteins
CA2391080A1 (en) * 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties

Also Published As

Publication number Publication date
BR0203394A (pt) 2004-05-11
EP1319712A3 (en) 2003-11-12
US20030124115A1 (en) 2003-07-03
EP1319712B1 (en) 2010-03-10
MXPA02008131A (es) 2004-12-13
GB0218252D0 (en) 2002-09-11
GB2382580B (en) 2003-10-08
AR036384A1 (es) 2004-09-01
MY122935A (en) 2006-05-31
JP2003169671A (ja) 2003-06-17
CN100390201C (zh) 2008-05-28
RU2002123438A (ru) 2004-03-27
BRPI0203394B1 (pt) 2015-12-01
DE10235248B4 (de) 2004-12-23
DE60235603D1 (de) 2010-04-22
JP3860097B2 (ja) 2006-12-20
CN1421461A (zh) 2003-06-04
CA2394572C (en) 2007-08-14
US7098318B2 (en) 2006-08-29
RU2225220C1 (ru) 2004-03-10
GB2382580A (en) 2003-06-04
TWI237056B (en) 2005-08-01
KR100467750B1 (ko) 2005-01-24
WO2003046013A1 (en) 2003-06-05
FR2832716A1 (fr) 2003-05-30
DE10235248A1 (de) 2003-06-12
SG117416A1 (en) 2005-12-29
CA2394572A1 (en) 2003-05-29
FR2832716B1 (fr) 2004-12-03
ITMI20021803A1 (it) 2003-05-30
ATE460483T1 (de) 2010-03-15
ES2339426T3 (es) 2010-05-20
NZ520442A (en) 2003-10-31
AU2002300359B2 (en) 2004-12-23
EP1319712A2 (en) 2003-06-18
KR20030044272A (ko) 2003-06-09

Similar Documents

Publication Publication Date Title
AU2002300734A1 (en) Fusion protein having enhanced in vivo erythropoietin activity
ZA200206172B (en) Fusion protein having enhanced in vivo activity of erythropoietin.
AU2002300359A1 (en) Fusion Protein Having Enhanced in vivo Activity of Erythropoietin
HUP0401300A3 (en) Bifunctional fusion proteins with glucocerebrosidase activity
GB0130228D0 (en) Protein
EP1365022A4 (en) ADIPONECTIN-ASSOCIATED PROTEIN
GB0218205D0 (en) Human ZZAP1 protein
GB0108079D0 (en) Protein
GB0101760D0 (en) Novel protein
GB0217548D0 (en) Four human zinc-finger-containing proteins:MDZ3.MDZ4,MDZ7 and MDZ12
GB2370039B (en) Producing protein arrays and fusion protein for use therein
GB0102447D0 (en) Protein variants and uses thereof
GB0130721D0 (en) Protein
GB0106318D0 (en) Protein
GB0121840D0 (en) Modified enzyme
GB0224687D0 (en) Protein
GB0120927D0 (en) Protein
GB0125071D0 (en) Protein
GB0125072D0 (en) Protein
GB0130740D0 (en) Protein
GB0125516D0 (en) Protein
GB0125714D0 (en) Protein
GB0125717D0 (en) Protein
GB0124637D0 (en) Protein
GB0129631D0 (en) Protein